German CVC as most active corporate investor in the European life sciences sector

With 44 deals, the corporate venture arm of Boehringer Ingelheim was the most active corporate investor in the European life science market in the last five years.

The only other investor having reached the top 5 ranking in all three sectors (MedTech, HealthTech, and BioTech) was GV, with a total of 29 deals.

Compared to the Biotech sector, MedTech and HealthTech seem to be still driven by private institutional investors as CVC investments appear to be low.

Large pharmaceutical companies such as Boehringer Ingelheim, Merck, Novartis, and Johnson & Johnson continue to play an important role in VC financing in the BioTech sector.

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here:

[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]